CID16020046

CID16020046

CAT N°: 15247
Price:

From 54.00 45.90

CID16020046 is a GPR55 inverse agonist that antagonizes GPR55 constitutive activity with an IC50 value of 15 ?M.{29659} It inhibits GPR55-mediated ERK1/2 phosphorylation, LPI-induced Ca2+ signaling (IC50 = 0.21 ?M in HEK-GPR55 cells), and GPR55-mediated transcription factor activation.{29659} It does not affect ERK1/2 phosphorylation or transcription factor activation in CB receptor expressing cells and demonstrates weak activity against a broad spectrum of other GPCRs, ion channels, kinases, and nuclear receptors.{29659} This compound has been shown to block GPR55-mediated endothelial wound healing and reverse LPI-inhibited platelet aggregation.{29659}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 4-[4,6-dihydro-4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxopyrrolo[3,4-c]pyrazol-5(1H)-yl]-benzoic acid
  • Correlated keywords
    • GPR55 inverse agonist LPI CID-16020046 GPR-55 G protein-coupled receptor GPCR
  • Product Overview:
    CID16020046 is a GPR55 inverse agonist that antagonizes GPR55 constitutive activity with an IC50 value of 15 ?M.{29659} It inhibits GPR55-mediated ERK1/2 phosphorylation, LPI-induced Ca2+ signaling (IC50 = 0.21 ?M in HEK-GPR55 cells), and GPR55-mediated transcription factor activation.{29659} It does not affect ERK1/2 phosphorylation or transcription factor activation in CB receptor expressing cells and demonstrates weak activity against a broad spectrum of other GPCRs, ion channels, kinases, and nuclear receptors.{29659} This compound has been shown to block GPR55-mediated endothelial wound healing and reverse LPI-inhibited platelet aggregation.{29659}

We also advise you